Background: Ocular inflammatory events following COVID-19 vaccination have been reported in the adult population.
Methods: Multinational case series of patients under the age of 18 diagnosed with ocular inflammatory events within 28 days of COVID-19 vaccination.
Results: Twenty individuals were included. The most common event was anterior uveitis ( = 8, 40.0%), followed by intermediate uveitis (7 patients, 35%), panuveitis (4 patients, 20%), and posterior uveitis (1 patient, 5%). The event was noticed in the first week after vaccination in 11 patients (55.0%). Twelve patients (60.0%) had a previous history of intraocular inflammatory event. Patients were managed with topical corticosteroids ( = 19, 95.0%), oral corticosteroids ( = 10, 50.0%), or increased dose of immunosuppressive treatment ( = 6, 30.0%). Thirteen patients (65.0%) had a complete resolution of the ocular event without complications. All patients had a final visual acuity unaffected or less than three lines of loss.
Conclusion: Ocular inflammatory events may happen in the paediatric population following COVID-19 vaccination. Most events were successfully treated, and all showed a good visual outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2023.2220782 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Estimation of microbiota and interleukin-1 beta in tears and conjunctival secretions of patients with ocular defects after using unilateral ocular prosthesis.
J Prosthet Dent
January 2025
Professor, Department of Ophthalmology, King George's Medical University, Lucknow, India.
Statement Of Problem: Clinical studies evaluating the levels of interleukin-1 beta (IL-1β) in tears and conjunctival secretions of patients with ocular defects after using ocular prostheses are lacking. Therefore, a comparative evaluation of IL-1β levels in the defective eye before and after placement of an ocular prosthesis is needed.
Purpose: The purpose of this clinical study was to compare the microbiota and IL-1β in tears and conjunctival secretions of patients with an ocular defect after using an ocular prosthesis.
Topographic corneal changes in children with moderate to severe blepharokeratoconjunctivitis.
J AAPOS
January 2025
Department of Ophthalmology, University of California San Francisco, San Francisco, California. Electronic address:
Purpose To determine the corneal topographic characteristics of children with blepharokeratoconjunctivitis (BKC), a chronic inflammatory ocular surface disease involving the lid margin, conjunctiva, and cornea. Methods The corneal topography of 21 children diagnosed with BKC between March 2008 and June 2019 at a single institution were reviewed retrospectively. Pachymetry and asymmetry indices were also analyzed.
View Article and Find Full Text PDFPurpose: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have risen exponentially in usage and have been shown to exert neuroprotective and anti-inflammatory effects across multiple organ systems. This study investigates whether GLP-1RAs influence the risk for age-related ocular diseases.
Design: Retrospective cohort study.
Arctiin suppress Th17 cells response and ameliorates experimental autoimmune uveitis through JAK/STAT signaling.
Cell Immunol
January 2025
Department of Rheumatology, Jincheng People 's Hospital, Shanxi Province, China.
Conventional treatments for autoimmune uveitis, such as corticosteroids and systemic immunosuppressants, often result in adverse side effects, prompting the need for therapies targeting specific molecular pathways. This study investigates the effects of Arctiin, known for its diverse biological properties, on experimental autoimmune uveitis (EAU) through its action on Th17 cells and the JAK/STAT signaling pathway. Our findings reveal that Arctiin significantly alleviates EAU by reducing clinical scores, inflammatory cell infiltration, and levels of inflammatory cytokines like IL-17 and TNF-α in the eye.
View Article and Find Full Text PDFBilateral Choroidal Metastases from Primary Cutaneous Melanoma Following Nivolumab Discontinuation: A Case Report.
Ocul Immunol Inflamm
January 2025
Ocular Oncology Service, Institute of Oncology, Tecnologico de Monterrey, Monterrey, Mexico.
Purpose: To present the case of a young patient with BRAF V600E-mutant cutaneous melanoma who developed bilateral choroidal metastases complicated by neovascular glaucoma (NVG) in both eyes following the interruption of nivolumab therapy.
Methods: A 28-year-old female with primary cutaneous melanoma of the left hand underwent surgical resection and adjuvant nivolumab. Immunotherapy was discontinued due to immune-related acute interstitial nephritis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!